Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

Compare

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VX1 Analyst Ratings

Moderate Buy

15 Buy

10 Hold

0 Sell

Based on 25 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€416.72

▲(26.59% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €416.72 with a high forecast of €534.79 and a low forecast of €343.67. The average price target represents a 26.59% change from the last price of €329.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"329":"€329","432":"€432","535":"€535","380.5":"€380.5","483.5":"€483.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":534.78639552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€534.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":416.7220143552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€416.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":343.66882148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€343.67</span>\n  </div></div>","useHTML":true}}],"tickPositions":[329,380.5,432,483.5,535],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.45,346.16818427076925,361.88636854153845,377.6045528123077,393.32273708307696,409.04092135384616,424.7591056246154,440.4772898953846,456.1954741661539,471.91365843692313,487.63184270769233,503.3500269784616,519.0682112492308,{"y":534.78639552,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.45,337.08630879655385,343.72261759310766,350.3589263896615,356.9952351862154,363.63154398276924,370.26785277932305,376.9041615758769,383.5404703724307,390.1767791689846,396.81308796553844,403.4493967620923,410.0857055586461,{"y":416.7220143552,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.45,331.46683242153847,332.4836648430769,333.5004972646154,334.51732968615386,335.5341621076923,336.55099452923076,337.56782695076924,338.5846593723077,339.60149179384615,340.61832421538463,341.6351566369231,342.65198905846154,{"y":343.66882148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":447.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":420.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":433.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":443.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€534.79

Average Price Target€416.72

Lowest Price Target€343.67

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Buy

―

Reiterated

09/25/25

Vertex Pharmaceuticals' Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating

David Risinger

Leerink Partners

€392.52→€390.81

Buy

18.71%

Upside

Upgraded

09/25/25

Vertex Pharmaceuticals upgraded to Outperform from Market Perform at LeerinkVertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink

Tazeen Ahmad

Bank of America Securities

€484.22

Buy

47.09%

Upside

Reiterated

09/23/25

Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating

Cory Kasimov

Evercore ISI

€437.09→€407.09

Buy

23.66%

Upside

Reiterated

09/11/25

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Evan Seigerman

BMO Capital

€454.23

Buy

37.98%

Upside

Reiterated

09/11/25

Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning

Geoff Meacham

Citi

€471.37

Buy

43.19%

Upside

Reiterated

09/10/25

Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics

Christopher Raymond

Raymond James

€343.67

Hold

4.40%

Upside

Initiated

09/02/25

Vertex Pharmaceuticals initiated with a Market Perform at Raymond JamesVertex Pharmaceuticals initiated with a Market Perform at Raymond James

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

Salveen Richter

Goldman Sachs

€534.79

Buy

62.45%

Upside

Reiterated

08/11/25

Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Whitney Ijem

Canaccord Genuity

€363.38→€352.24

Hold

7.00%

Upside

Reiterated

08/06/25

Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord

Debjit Chattopadhyay

Guggenheim

€478.22→€467.94

Buy

42.14%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Mohit Bansal

Wells Fargo

€394.23

Buy

19.76%

Upside

Upgraded

08/06/25

Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position

Joon Lee

Truist Financial

€445.66→€419.94

Buy

27.57%

Upside

Reiterated

08/05/25

Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Andrew Fein

H.C. Wainwright

€471.37→€409.66

Buy

24.44%

Upside

Reiterated

08/05/25

Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright

Joseph Stringer

Needham

―

Hold

―

Reiterated

08/05/25

Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Buy

―

Reiterated

09/25/25

Vertex Pharmaceuticals' Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating

David Risinger

Leerink Partners

€392.52→€390.81

Buy

18.71%

Upside

Upgraded

09/25/25

Vertex Pharmaceuticals upgraded to Outperform from Market Perform at LeerinkVertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink

Tazeen Ahmad

Bank of America Securities

€484.22

Buy

47.09%

Upside

Reiterated

09/23/25

Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating

Cory Kasimov

Evercore ISI

€437.09→€407.09

Buy

23.66%

Upside

Reiterated

09/11/25

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Evan Seigerman

BMO Capital

€454.23

Buy

37.98%

Upside

Reiterated

09/11/25

Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning

Geoff Meacham

Citi

€471.37

Buy

43.19%

Upside

Reiterated

09/10/25

Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics

Christopher Raymond

Raymond James

€343.67

Hold

4.40%

Upside

Initiated

09/02/25

Vertex Pharmaceuticals initiated with a Market Perform at Raymond JamesVertex Pharmaceuticals initiated with a Market Perform at Raymond James

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

Salveen Richter

Goldman Sachs

€534.79

Buy

62.45%

Upside

Reiterated

08/11/25

Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Whitney Ijem

Canaccord Genuity

€363.38→€352.24

Hold

7.00%

Upside

Reiterated

08/06/25

Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord

Debjit Chattopadhyay

Guggenheim

€478.22→€467.94

Buy

42.14%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Mohit Bansal

Wells Fargo

€394.23

Buy

19.76%

Upside

Upgraded

08/06/25

Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position

Joon Lee

Truist Financial

€445.66→€419.94

Buy

27.57%

Upside

Reiterated

08/05/25

Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Andrew Fein

H.C. Wainwright

€471.37→€409.66

Buy

24.44%

Upside

Reiterated

08/05/25

Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright

Joseph Stringer

Needham

―

Hold

―

Reiterated

08/05/25

Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month

xxx

Success Rate

24/32 ratings generated profit

Average Return

+4.15%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.15% per trade.

3 Months

xxx

Success Rate

21/31 ratings generated profit

Average Return

+6.15%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.74% of your transactions generating a profit, with an average return of +6.15% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

22/32 ratings generated profit

Average Return

+19.89%

reiterated a buy rating 18 days ago

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +19.89% per trade.

2 Years

xxx

Success Rate

26/31 ratings generated profit

Average Return

+24.42%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.87% of your transactions generating a profit, with an average return of +24.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VX1 has received 33 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 416.72.

Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €3.93 with a range of €3.70 to €4.28. The previous quarter’s EPS was €3.86. VX1 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.82% of the time in the same period. In the last calendar year VX1 has Outperformed its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.61B with a range of €2.52B to €2.68B. The previous quarter’s sales results were €2.55B. VX1 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 54.41% of the time in the same period. In the last calendar year VX1 has Outperformed its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 416.72.

What is DE:VX1’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 26.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Vertex Pharmaceuticals a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 10 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s share price target?

The average share price target for Vertex Pharmaceuticals is 416.72. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €534.79 ,and the lowest forecast is €343.67. The average share price target represents 26.59% Increase from the current price of €329.2.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of Vertex Pharmaceuticals?

To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

VX1 Analyst Ratings

VX1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VX1 Analyst Recommendation Trends

VX1 Financial Forecast

VX1 Earnings Forecast

VX1 Sales Forecast

VX1 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts